Guideline 101: British guideline on the management of asthma - Supporting material

The full printed version of the guideline is available. Included on this page is supporting material which is not available in the printed copy.

SEARCH STRATEGIES

Acute Asthma search narrative 2003		(1.19M)
Delivery of Care search narrative 2003		(77K)
Diagnosis search narrative 2003		(85K)
Inhaler Devices search narrative 2003		(54K)
Non Pharmacological search narrative 2003		(98K)
Outcomes Audit search narrative 2003		(55K)
Patient Education search narrative 2003		(83K)
Pharmacological search narrative 2003		(124K)
Pregnancy search narrative 2003		(70K)
Systematic Reviews search narrative 2003		(62K)
Inhaler Devices search narrative 2004		(62K)
Outcomes Audit search narrative 2004		(70K)
Pharmacological search narrative 2004		(129K)
Pregnancy search narrative 2004		(81k)
Systematic Reviews search narrative 2004		(64K)
Diagnosis search narrative 2006		(74k)
Non Pharmacological search narrative 2006		(80K)
Patient Education search narrative 2006		(61K)
Pharmacological search narrative 2006		(98K)
Pregnancy search narrative 2006		(32K)
Diagnosis search narrative 2007		(85K)
Difficult Asthma search narrative 2007		(72K)
Pharmacological search narrative 2007		(72K)
Adolescents search narrative 2009		(12K)
Monitoring search narrative 2009		(9K)
Pharmacological search narrative 2009		(47K)

Evidence tables

• Evidence table 4.1: Inhaled short acting beta 2 agonists
• Evidence table 4.10: Rhinitis
• Evidence table 4.11a: Add-on drugs for inhaled steroids: Chromones
• Evidence table 4.11b: Add-on drugs for inhaled steroids: Long acting or oral B2 agonists
• Evidence table 4.11c: Add-on drugs for inhaled steroids: Anticholinergics
• Evidence table 4.11d: Add-on drugs for inhaled steroids: Theophylline, beclomethasone diproponate, budesonide
• Evidence table 4.13a: Immunosuppresive agents
• Evidence table 4.15: Mometasone Furoate dry powder inhalation evidence
• Evidence table 4.19: Allergic bronchopulmonary aspergillosis
• Evidence table 4.2: Ipratopium bromide
• Evidence table 4.21: Aspirin intolerant asthma
• Evidence table 4.22: Combined therapy of inhaled steroids and long acting B2 agonist
• Evidence table 4.23: Anti IgE in asthma
• Evidence table 4.24a: Other preventor therapies - Chromones in children aged 5-12
• Evidence table 4.24b: Other preventor therapies - Chromones in children aged <5
• Evidence table 4.25: Budesonide vs beclomethasone
• Evidence table 4.3a: Long acting B2 agonists in exercise induced asthma
• Evidence table 4.3b: Ketotifen for exercise-induced asthma
• Evidence table 4.3c: Theophyllines in exercise-induced asthma
• Evidence table 4.3d: Leukotriene receptor antagonists in exercise induced asthma
• Evidence table 4.3e: Anti-histamines for exercise-induced asthma
• Evidence table 4.3f: Anti-cholinergic therapy for exercise-induced asthma
• Evidence table 4.3g: Oral B2 agonists for exercise induced asthma
• Evidence table 4.4a: Inhaled corticosteroid vs theophylline
• Evidence table 4.4c: Inhaled corticosteroid vs leukotriene receptor antagonists
• Evidence table 4.4d: Leukotriene receptor antagonists with short-acting beta-agonists
• Evidence table 4.4j: Do Chromones work as first line preventor in children >5 years?
• Evidence table 4.7: High dose step-down
• Evidence table 4.8c: Children with poor asthma control on ICS – Is addition of leukotriene receptor antagonists helpful?
• Evidence table 4.9: Exacerbation